3,093 results match your criteria Polymyalgia Rheumatica


Towards a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group.

J Rheumatol 2019 Feb 1. Epub 2019 Feb 1.

From the Department of Rheumatology, Austin Health, Heidelberg VIC, Australia; Department of Medicine, University of Melbourne, Parkville VIC, Australia; Department of Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom; Norwich Medical School, University of East Anglia, Norwich, United Kingdom; Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, Keele, Staffordshire, United Kingdom; PMR-GCA Scotland, Dundee, Angus, United Kingdom; PMR-GCA North East, Kibblesworth, Tyne and Wear, United Kingdom.; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; SDG LLC, Cambridge, Massachusetts, United States of America; Rheumatology Unit, Royal Adelaide Hospital, Adelaide, SA, Australia; Discipline of Medicine, The University of Adelaide, Adelaide, SA, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom and NIHR-Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. Address correspondence to Dr Claire Owen, Rheumatology Department, Austin Health - Repatriation Campus Level 1, North Wing, 300 Waterdale Road, Heidelberg West VIC, Australia 3081. Email:

Objective: To report the progress of the OMERACT Polymyalgia Rheumatica (PMR) Working Group in selecting candidate instruments for a core outcome measurement set.

Methods: A systematic literature review identified outcomes measured and instruments used in PMR studies, and a respondent survey and raw data analysis assessed their domain match and feasibility.

Results: Candidate instruments were identified for pain (VAS/NRS), stiffness (VAS/NRS and duration) and physical function (HAQ-DI/MHAQ). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181050DOI Listing
February 2019
1 Read

Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.

Prostate Cancer Prostatic Dis 2019 Jan 28. Epub 2019 Jan 28.

Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.

Background: Androgen deprivation therapy (ADT) has been a mainstay of treatment for advanced prostate cancer (PCa), but limited studies have been performed to investigate the association between ADT and autoimmune diseases.

Methods: We conducted a population-based nationwide cohort study of 17,168 patients newly diagnosed with PCa between 1996 and 2013 using the National Health Insurance Research Database (NHIRD) of Taiwan. Cox proportional hazards models with 1:1 propensity score-matched analysis were used to investigate the association between ADT use and the risk of autoimmune diseases. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-019-0130-9
Publisher Site
http://dx.doi.org/10.1038/s41391-019-0130-9DOI Listing
January 2019
6 Reads

Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses.

Ann Rheum Dis 2019 Jan 22. Epub 2019 Jan 22.

Department of Rheumatology, University Hospital Basel, Basel, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214704DOI Listing
January 2019
2 Reads
10.377 Impact Factor

Hereditary Hemochromatosis Associations with Frailty, Sarcopenia and Chronic Pain: Evidence from 200,975 Older UK Biobank Participants.

J Gerontol A Biol Sci Med Sci 2019 Feb;74(3):337-342

Epidemiology and Public Health Group, University of Exeter Medical School, UK.

Background: Iron is essential for life but contributes to oxidative damage. In Northern-European ancestry populations, HFE gene C282Y mutations are relatively common (0.3%-0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/gerona/gly270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376086PMC
February 2019
2 Reads
5.416 Impact Factor

Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis.

Rheumatology (Oxford) 2019 Jan 10. Epub 2019 Jan 10.

Department of Rheumatology, Internal Medicine & Geriatrics, Pomeranian Medical University, Szczecin, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key431DOI Listing
January 2019
4 Reads

The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series.

Autoimmun Rev 2019 Jan 11. Epub 2019 Jan 11.

Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, Pisa 56126, Italy. Electronic address:

Graves' disease (GD) and autoimmune thyroiditis (AT) are the two main clinical presentations of AITD, and their clinical hallmarks are thyrotoxicosis and hypothyroidism, respectively. GD, and AT, can be associated with other organ specific, or systemic autoimmune diseases in the same patient. However discordant results have been reported in the literature about the possible associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.10.001DOI Listing
January 2019
11 Reads

Mizoribine is as Effective as Methotrexate for the Treatment of Polymyalgia Rheumatica: A Retrospective Case Series Analysis.

Arch Rheumatol 2018 Sep 15;33(3):302-308. Epub 2018 Jan 15.

St. Luke's International University, St. Luke's International Hospital, Immuno-Rheumatology Center, Tokyo, Japan.

Objectives: This study aims to evaluate the efficacy and safety of mizoribine (MZR) as a steroid-sparing agent compared to methotrexate (MTX) in the treatment of polymyalgia rheumatica in elderly patients.

Patients And Methods: Twenty-four patients (9 males, 15 females; mean age 71.7 years; range 50 to 86 years) diagnosed with polymyalgia rheumatica between April 1998 and August 2014, who received prednisone in combination with either MTX or MZR, were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5606/ArchRheumatol.2018.6418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328222PMC
September 2018
1 Read

Development of polymyalgia rheumatica during hospitalization and diagnosis based on history taking by physical and occupational therapists.

J Gen Fam Med 2019 Jan 4;20(1):28-30. Epub 2018 Dec 4.

Department of Medicine Mito Kyodo General Hospital University of Tsukuba Mito Ibaraki Japan.

Polymyalgia rheumatica (PMR) is frequently reported in the outpatient setting and presents with pain, morning stiffness, mild fever, and fatigue. However, the clinical course of PMR during hospitalization is unknown. We report a case of PMR that developed during hospitalization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jgf2.224DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321836PMC
January 2019
1 Read

Examining management and research priorities in patients with polymyalgia rheumatica: a primary care questionnaire survey.

Clin Rheumatol 2019 Jan 7. Epub 2019 Jan 7.

Research Institute for Primary Care and Health Sciences, Keele University, Keele, UK.

Introduction/objectives: Polymyalgia rheumatica (PMR) is a common inflammatory disorder that is usually managed with oral glucocorticoids, which although effective can cause significant adverse events. Support group survey data suggests length of glucocorticoid treatment and managing side effects are key priority areas of management for patients. Recognising that not all patients will access patient support organisations, our objective was to identify priorities for PMR management and research among primary care PMR patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-04405-0DOI Listing
January 2019
2 Reads

Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study.

Clin Rheumatol 2019 Jan 7. Epub 2019 Jan 7.

Department of Internal Medicine and Clinical Immunology, Normandie Univ, UNICAEN, CHU de Caen Normandie, Avenue de la Côte de Nacre, 14000, Caen, France.

Introduction: Some studies suggest that there is an increased risk of malignancies in giant cell arteritis (GCA). We aimed to describe the clinical characteristics and outcomes of GCA patients with concomitant malignancy and compare them to a GCA control group.

Method: Patients with a diagnosis of GCA and malignancy and with a maximal delay of 12 months between both diagnoses were retrospectively included in this study and compared to a control group of age-matched (3:1) patients from a multicenter cohort of GCA patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10067-018-04407-y
Publisher Site
http://dx.doi.org/10.1007/s10067-018-04407-yDOI Listing
January 2019
6 Reads

Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series.

Respir Med Case Rep 2019 21;26:126-130. Epub 2018 Dec 21.

Regional Referral Center for Rare Lung Diseases, A. O. U. "Policlinico-Vittorio Emanuele" Dpt. of Clinical and Experimental Medicine, University of Catania, Italy.

Introduction: Severe morning stiffness with painful involvement of the girdles are often referred by patients with Interstitial Lung Disease (ILD), but the association between ILD and Polymyalgia Rheumatica (PMR) is rarely reported. The purpose of the work is to describe a series of patients classified as having PMR with ILD.

Material And Methods: We retrospectively enrolled patients with a diagnosis of PMR referred to our center during the previous year for respiratory symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2018.12.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307098PMC
December 2018
2 Reads

Glucocorticoid-Induced Osteoporosis.

N Engl J Med 2018 Dec;379(26):2547-2556

From the Yale School of Medicine, New Haven, CT (L.B.); and the University of Oklahoma Health Sciences Center, Oklahoma City (M.B.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcp1800214DOI Listing
December 2018
2 Reads

Update on the epidemiology, risk factors, and outcomes of systemic vasculitides.

Best Pract Res Clin Rheumatol 2018 04 2;32(2):271-294. Epub 2018 Nov 2.

Department of Rheumatology, Hospital of Bruneck, Bruneck, Italy; Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria.

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and giant cell arteritis (GCA) are the most common primary systemic vasculitides of the adult population, while polymyalgia rheumatica (PMR) is a clinical syndrome often associated with GCA. Incidence and prevalence rates of AAV have been increasing in the last decades, whereas those of GCA and PMR have remained stable. The mutual interplay between environmental and genetic risk factors leading to the development of these diseases has been further analyzed in the last years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.berh.2018.09.001DOI Listing
April 2018
2 Reads

Comorbidities in polymyalgia rheumatica: a systematic review.

Arthritis Res Ther 2018 Nov 20;20(1):258. Epub 2018 Nov 20.

Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, Keele, ST5 5BG, UK.

Background And Aim: Comorbidities are known to exist in many rheumatological conditions. Polymyalgia rheumatica (PMR) is a common inflammatory rheumatological condition affecting older people which, prior to effective treatment, causes severe disability. Our understanding of associated comorbidities in PMR is based only on case reports or series and small cohort studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-018-1757-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247740PMC
November 2018
3 Reads

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.

Eur J Cancer 2019 Jan 17;106:12-23. Epub 2018 Nov 17.

Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Germany. Electronic address:

Aim: To characterise clinical presentation, laboratory and histopathologic characteristics and assess the treatment and outcome of neuromuscular side-effects of checkpoint therapy.

Methods: The side-effect registry and the institutional database from ten skin cancer centres were queried for reports on myositis and neuromuscular side-effects induced by checkpoint inhibitors. In total, 38 patients treated with ipilimumab, tremelimumab, nivolumab and pembrolizumab for metastatic skin cancer were evaluated and characterised. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183140
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.09.033DOI Listing
January 2019
14 Reads

Paraneoplastic Syndrome Presenting with Polymyalgia Rheumatica-like Accumulations on F-fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography.

Intern Med 2018 Nov 19. Epub 2018 Nov 19.

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.

A 70-year-old woman presented with a fever and pain in both lower extremities and the right shoulder and right upper arm continuously for approximately 3 months. F-fluorodeoxyglucose-positron emission tomography/computed tomography (F-FDG/PET-CT) revealed the accumulation of FDG in the right shoulder, lumbar spinous processes, both ischial tuberosities, and both hips and greater trochanters, indicating polymyalgia rheumatica (PMR). In addition, upper gastrointestinal endoscopy revealed esophageal carcinoma. Read More

View Article

Download full-text PDF

Source
https://www.jstage.jst.go.jp/article/internalmedicine/advpub
Publisher Site
http://dx.doi.org/10.2169/internalmedicine.1847-18DOI Listing
November 2018
9 Reads

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

Lancet Oncol 2018 Dec 12;19(12):1579-1589. Epub 2018 Nov 12.

Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:

Background: Immune checkpoint inhibitors (ICIs) have substantially improved clinical outcomes in multiple cancer types and are increasingly being used in early disease settings and in combinations of different immunotherapies. However, ICIs can also cause severe or fatal immune-related adverse-events (irAEs). We aimed to identify and characterise cardiovascular irAEs that are significantly associated with ICIs. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183060
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30608-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287923PMC
December 2018
11 Reads

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

Eur J Cancer 2018 Dec 13;105:88-102. Epub 2018 Nov 13.

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department, University of Melbourne, Melbourne, Australia. Electronic address:

Importance: Rheumatic immune-related adverse events (irAEs) occur in approximately 10-20% of anti-programmed death 1 (anti-PD1)-treated cancer patients. There are limited data on the natural history, optimal treatment and long-term oncological outcomes of patients with rheumatic irAEs.

Objective: The objective of the study was to describe the spectrum and natural history of rheumatic irAEs and the potential impact of rheumatic irAEs and immunomodulators on anti-PD1 tumour efficacy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183139
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.09.027DOI Listing
December 2018
19 Reads

Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study.

Clin Epidemiol 2018 16;10:1533-1543. Epub 2018 Oct 16.

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark,

Objective: It has been suggested that a hyper-effective immune system ("hyper-immunity") is central to the pathogenesis of giant cell arteritis and polymyalgia rheumatica (GCA/PMR). We examined if a low risk of infections, as a marker of hyper-immunity, can predict increased subsequent risk of GCA/PMR.

Patients And Methods: We conducted a population-based case-control study including all patients aged ≥50 years with incident GCA/PMR diagnosed between 1997 and 2012 in Northern Denmark. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/does-low-risk-of-infections-as-a-m
Publisher Site
http://dx.doi.org/10.2147/CLEP.S158293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201992PMC
October 2018
13 Reads

[Glucocorticoid sensitive bilateral leg swelling in an 85-year-old woman presenting with polymyalgia rheumatica: A case report].

Rev Med Interne 2018 Oct 31. Epub 2018 Oct 31.

Service de rhumatologie, centre hospitalier René-Dubos, 6, avenue de l'Île-de-France, 95301 Pontoise, France. Electronic address:

Introduction: Polymyalgia rheumatica (PMR) can be associated with distal swelling indicating an associated RS3PE syndrome. We report a case of PMR associated with oedema of the lower limbs, which resolved rapidly under glucocorticoid therapy.

Case Report: A 85-year-old woman presented with a 4 month history of PMR responding to the 2012 EULAR/ACR classification criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.revmed.2018.10.004DOI Listing
October 2018
3 Reads

Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica is Uncommon but May Be Enhanced by Amino Bisphosphonates.

J Rheumatol 2018 Nov 1. Epub 2018 Nov 1.

From the Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy. A. Giollo, MD, Rheumatology Unit, Department of Medicine, University of Verona; M. Rossini, MD, PhD, Rheumatology Unit, Department of Medicine, University of Verona; F. Bettili, MD, Rheumatology Unit, Department of Medicine, University of Verona; F. Ghellere, MD, Rheumatology Unit, Department of Medicine, University of Verona; E. Fracassi, MD, PhD, Rheumatology Unit, Department of Medicine, University of Verona; L. Idolazzi, MD, PhD, Rheumatology Unit, Department of Medicine, University of Verona; D. Gatti, MD, PhD, Rheumatology Unit, Department of Medicine, University of Verona; O. Viapiana, MD, PhD, Rheumatology Unit, Department of Medicine, University of Verona. Address correspondence to Dr. A. Giollo, Rheumatology Unit, Department of Medicine, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy. E-mail: Accepted for publication August 8, 2018.

Objective: The duration of treatment with glucocorticoids (GC) in polymyalgia rheumatica (PMR) is often longterm. Amino bisphosphonates (N-BP) are used in PMR for the prevention of GC-induced osteoporosis, but they could also have immunomodulatory properties. Whether they can be effective as an adjuvant treatment in PMR is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180324DOI Listing
November 2018
3 Reads

Incidence of inflammatory polyarthritis in polymyalgia rheumatica: a population-based cohort study.

Ann Rheum Dis 2018 Oct 26. Epub 2018 Oct 26.

Norwich Medical School, Bob Champion Research and Education Building, University of East Anglia, Norwich, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214386DOI Listing
October 2018
3 Reads

Corticosteroid Tapering Regimens in Rheumatic Disease: A Systematic Review.

J Clin Rheumatol 2018 Oct 23. Epub 2018 Oct 23.

Background/objective: Corticosteroids have long been used to effectively treat rheumatic disorders, but adverse effects associated with extended-duration regimens generate disagreement among clinicians regarding optimal tapering strategies. The objective of this systematic review was to assess clinical outcomes of differing tapering regimens after corticosteroid monotherapy in adults with rheumatic disorders.

Methods: A systematic review of Medline/PubMed, Embase, Cochrane, International Pharmaceutical Abstracts, Web of Science, Scopus, Global Index Medicus, American College of Rheumatology, gray literature, and reference lists up to June 27, 2018, was conducted by 2 authors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000917DOI Listing
October 2018
12 Reads

Challenges of diagnosing and managing polymyalgia rheumatica: a multi-methods study in UK general practice.

Br J Gen Pract 2018 Nov;68(676):e783-e793

Institute for Primary Care and Health Sciences, NIHR research professor in general practice, NIHR CLAHRC West Midlands, deputy director, NIHR School for Primary Care Research, and training lead, Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, Keele.

Background: Polymyalgia rheumatica (PMR) is one of the most common inflammatory arthritic disorders seen in older individuals. Most patients with PMR are diagnosed and managed exclusively in general practice, yet primary care-focused research is lacking.

Aim: To identify and explore the challenges of diagnosis and management of PMR in general practice. Read More

View Article

Download full-text PDF

Source
http://bjgp.org/lookup/doi/10.3399/bjgp18X699557
Publisher Site
http://dx.doi.org/10.3399/bjgp18X699557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193770PMC
November 2018
13 Reads

Swollen joints and peripheral arthritis are signs of malignancy in polymyalgia rheumatica.

Mod Rheumatol 2018 Dec 18:1-4. Epub 2018 Dec 18.

h Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.

Aim: To analyze the clinical course and prognosis in patients diagnosed with polymyalgia rheumatica (PMR) complicated by the presence of malignancies.

Methods: We retrospectively screened the case files of 216 patients hospitalized in our department between 2011 and December 2016 for the results of a thorough physical examination and data on treatment for rheumatic diseases. We identified 53 patients with PMR according to Bird's criteria and 43 patients with 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for PMR, then analyzed the clinical and serologic manifestations of PMR in patients with (n = 6) and without (n = 47 in Bird' criteria, n = 37 in 2012 EULAR/ACR criteria) malignancy. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14397595.2018.1
Publisher Site
http://dx.doi.org/10.1080/14397595.2018.1538027DOI Listing
December 2018
12 Reads

Applications of PET Imaging in the Evaluation of Musculoskeletal Diseases Among the Geriatric Population.

Semin Nucl Med 2018 Nov 6;48(6):525-534. Epub 2018 Aug 6.

Department of Radiology, Hospital of University of Pennsylvania, Philadelphia, PA. Electronic address:

Medical imaging plays a particularly important role in the care of elderly patients, in whom complex symptomatology and a high prevalence of musculoskeletal diseases necessitate sensitive imaging modalities. MRI is the most commonly used imaging modality in the evaluation of various musculoskeletal disorders. The integration of positron emission technique and computed tomography as well as magnetic resonance imaging allows for generating complimentary data for accurate and quantitative diagnosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00012998183005
Publisher Site
http://dx.doi.org/10.1053/j.semnuclmed.2018.07.002DOI Listing
November 2018
11 Reads

A Comparative Study of Doppler Ultrasound against Temporary Artery Biopsy in the Diagnosis of Giant Cell Arteritis.

Reumatol Clin 2018 Oct 11. Epub 2018 Oct 11.

Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña, La Coruña, España.

Background: Giant cell arteritis (GCA) is a vasculitis that affects medium- and large-sized arteries. Temporal artery biopsy is the gold standard for diagnosis. In view of the high demand for temporal biopsies, the purpose of this study is to evaluate the usefulness of Doppler ultrasonography in patients with suspected giant cell arteritis, to determine its sensitivity and specificity as a diagnostic test and to determine whether it would be possible to substitute biopsy for ultrasonography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.reuma.2018.08.007DOI Listing
October 2018
2 Reads

Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study.

Ann Rheum Dis 2018 Dec 8;77(12):1750-1756. Epub 2018 Oct 8.

Arthritis UK Primary Care Centre, Keele University, Keele, UK.

Objective: Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in older people. Contemporary estimates of the incidence and prevalence are lacking, and no previous study has assessed treatment patterns at a population level. This study aims to address this. Read More

View Article

Download full-text PDF

Source
http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-21388
Publisher Site
http://dx.doi.org/10.1136/annrheumdis-2018-213883DOI Listing
December 2018
5 Reads

Use of contrast-enhanced magnetic resonance imaging of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumatica.

Clin Exp Rheumatol 2018 Sep-Oct;36 Suppl 114(5):86-95. Epub 2018 Oct 1.

Rheumazentrum Ruhrgebiet, Herne, Germany.

Objectives: To identify inflammatory pelvic structures of patients with polymyalgia rheumatica (PMR) by magnetic resonance imaging (MRI) in detail, searching for a disease-specific pattern.

Methods: A total of 40 contrast-enhanced pelvic MRIs of patients with a clinical diagnosis of PMR was reviewed by an experienced musculoskeletal radiologist who assessed all abnormalities semi-quantitatively, based on a predefined scoring system.

Results: The median (25th/75th percentiles) age of patients was 67 (55/73) years, median symptom duration 13 (6/22) weeks, 55% female, median CRP 1. Read More

View Article

Download full-text PDF

Source
January 2019
9 Reads

A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica.

Eur J Cancer 2018 Nov 1;103:281-283. Epub 2018 Oct 1.

Department of Internal Medicine, Nîmes University Hospital, Nîmes, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183133
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.07.318DOI Listing
November 2018
6 Reads

Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.

Arthritis Rheumatol 2018 Oct 3. Epub 2018 Oct 3.

Mayo Clinic, Rochester, Minnesota.

Objective: To describe the prevalence, clinical presentation, and management of rheumatic immune-related adverse effects (Rh-irAEs) from immune checkpoint inhibitor (ICI) therapy.

Methods: From a database of all patients who received any ICI at the Mayo Clinic Rochester, Minnesota campus between January 1, 2011 and March 1, 2018, we retrospectively identified those with Rh-irAEs, using diagnostic codes, search terms, and manual chart review.

Results: Of the 1,293 patients who received any ICI, Rh-irAEs were clinically diagnosed in 43. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40745DOI Listing
October 2018
1 Read

Cross-sectional survey of the undergraduate rheumatology curriculum in European medical schools: a EULAR School of Rheumatology initiative.

RMD Open 2018 21;4(2):e000743. Epub 2018 Sep 21.

Université Paris Diderot, USPC, UFR de Médecine, Paris, France.

Objectives: To survey the undergraduate rheumatic and musculoskeletal diseases (RMDs) curriculum content in a sample of medical schools across Europe.

Methods: The undergraduate musculoskeletal diseases and disability curriculum of University of Nottingham, UK, was used as a template to develop a questionnaire on curriculum content. The questionnaire elicited binary (yes/no) responses and included the option to provide additional information as free text. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2018-000743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157535PMC
September 2018
11 Reads

[Improved early diagnostics of rheumatic diseases : Monocentric experiences with an open rheumatological specialist consultation].

Z Rheumatol 2018 Nov;77(9):844-849

Standort Berlin Buch, Immanuel Krankenhaus Berlin, Lindenberger Weg 19, 13125, Berlin, Deutschland.

Aim Of The Project: To establish an open rheumatological outpatient consultation service for early diagnosis of inflammatory rheumatic diseases and initiation of further diagnostics and treatment.

Methods: In 2015 an open consultation service was initiated for patients with signs of an early rheumatic disease after referral by primary care physicians. Patients could attend once a week without the need for a prior appointment if they fulfilled at least one of the following criteria: positive rheumatoid factor, increased CRP, anti-CCP antibody or antinuclear antibody, joint pain or back pain for over 3 months, swollen joints, fever of unknown origin or acute muscle pain with or without headache of unknown origin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-018-0540-4DOI Listing
November 2018
2 Reads

Differences in clinical manifestations and prognosis of Chinese giant cell arteritis patients with or without polymyalgia rheumatica.

Ir J Med Sci 2018 Sep 24. Epub 2018 Sep 24.

Department of General Internal Medicine, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Science (CAMS) and Peking Union Medical College (PUMC), Beijing, 100730, China.

Background: The symptoms of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) frequently overlap in the elderly. Whether there are differences in clinical features or prognosis between GCA patients with or without PMR remains unknown.

Aims: To identify differences in clinical manifestation and prognosis between Chinese GCA patients with or without PMR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11845-018-1903-1DOI Listing
September 2018
3 Reads

Polymyalgia rheumatica due to pembrolizumab therapy.

J Oncol Pharm Pract 2018 Sep 24:1078155218800386. Epub 2018 Sep 24.

2 Lucy Curci Cancer Center, Eisenhower Medical Center, Rancho Mirage, CA, USA.

Pembrolizumab is a humanized anti-programmed cell death 1 antibody used for the therapy of several malignancies. While autoimmune adverse events are not uncommon with this agent, they are typically mild and self-limiting. Severe autoimmunity is rare but can be life-threatening. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1078155218800386
Publisher Site
http://dx.doi.org/10.1177/1078155218800386DOI Listing
September 2018
18 Reads

Polymyalgia Rheumatica (PMR) with Normal Values of Both Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) Concentration at the Time of Diagnosis in a Centenarian Man: A Case Report.

Authors:
Ciro Manzo

Diseases 2018 Sep 20;6(4). Epub 2018 Sep 20.

Internal and Geriatric Medicine Department, Azienda Sanitaria Locale Napoli 3 Sud, Rheumatologic Outpatient Clinic and Ambulatory of Geriatric Rheumatology, "Mariano Lauro" Hospital, 80065 Sant'Agnello, Italy.

The possibility that polymyalgia rheumatica (PMR) can be diagnosed when both ESR and CRP are normal at the time of diagnosis and before therapy with glucocorticoids, has been often discussed in the literature. We present a case report of a 100-year-old Caucasian man referred to our outpatient clinic, complaining of chronic pain in the shoulder and hip girdle associated with normal values of both ESR (21 mm/1st hour) and CRP (4 mg/dL). In the previous four months, several anti-inflammatory drugs and painkillers associated with physiotherapy treatments gave no significant improvement in pain and self-care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diseases6040084DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313638PMC
September 2018
4 Reads

Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches.

Int J Cancer 2019 Apr 26;144(7):1540-1549. Epub 2018 Oct 26.

PanGenEU Study Investigators (Additional file 1: Annex S1).

Deciphering the underlying genetic basis behind pancreatic cancer (PC) and its associated multimorbidities will enhance our knowledge toward PC control. The study investigated the common genetic background of PC and different morbidities through a computational approach and further evaluated the less explored association between PC and autoimmune diseases (AIDs) through an epidemiological analysis. Gene-disease associations (GDAs) of 26 morbidities of interest and PC were obtained using the DisGeNET public discovery platform. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31866DOI Listing
April 2019
4 Reads

Diagnostic FDG PET/CT findings in polymyalgia rheumatica.

QJM 2019 Feb;112(2):139-140

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/qjmed/hcy199DOI Listing
February 2019
5 Reads

The INCLUDE study: INtegrating and improving Care for patients with infLammatory rheUmatological DisordErs in the community; identifying multimorbidity: Protocol for a pilot randomized controlled trial.

J Comorb 2018 2;8(1):2235042X18792373. Epub 2018 Aug 2.

Arthritis Research UK Primary Care Centre, Research Institute for Primary Care and Health Sciences, Keele University, Keele, UK.

Background: Patients with inflammatory rheumatic conditions such as rheumatoid arthritis, polymyalgia rheumatica and ankylosing spondylitis are at increased risk of common comorbidities such as cardiovascular disease, osteoporosis and anxiety and depression which lead to increased morbidity and mortality. These associated morbidities are often un-recognized and under-treated. While patients with other long-term conditions such as diabetes are invited for routine reviews in primary care, which may include identification and management of co-morbidities, at present this does not occur for patients with inflammatory conditions, and thus, opportunities to diagnose and optimally manage these comorbidities are missed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2235042X18792373DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088485PMC
August 2018
4 Reads

A case of anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease complicated with tracheobronchial ulcers.

Respir Med Case Rep 2018 24;25:189-191. Epub 2018 Aug 24.

Department of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.

We herein report the first case, to our knowledge, of tracheobronchial ulcer with anti-melanoma differentiation-associated gene 5 (anti-MDA 5) antibody-positive interstitial lung disease (ILD). A 53-year-old man complained of shoulder and wrist pain and was suspected of having polymyalgia rheumatica at another hospital. Thereafter, treatment with prednisolone was started. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2018.08.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125794PMC
August 2018
2 Reads

Giant cell arteritis as unusual cause of critical arm ischemia.

J Vasc Surg Cases Innov Tech 2018 Sep 30;4(3):248-251. Epub 2018 Aug 30.

Department of Cardiac, Vascular and Thoracic Surgery, Kepler University Hospital, Linz, Austria.

Giant cell arteritis is an inflammatory vasculopathy of unknown etiology that typically affects the carotid artery and its branches. Symptomatic involvement of upper extremity arteries is uncommon. We report a case of a 70-year-old woman with polymyalgia rheumatica who presented with critical arm ischemia, constitutional symptoms, and elevated erythrocyte sedimentation rate. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24684287183008
Publisher Site
http://dx.doi.org/10.1016/j.jvscit.2018.05.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122378PMC
September 2018
5 Reads

Characteristics of Korean Patients with Polymyalgia Rheumatica: a Single Locomotive Pain Clinic Cohort Study.

J Korean Med Sci 2018 Sep 10;33(36):e241. Epub 2018 Aug 10.

Department of Physical and Rehabilitation Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Background: Polymyalgia rheumatica (PMR) is a common systemic inflammatory disease of the elderly; however, the clinical characteristics and therapeutic response of PMR in Korea have been rarely studied.

Methods: We reviewed the medical records of 54 Korean patients diagnosed with PMR between January 2009 and February 2017 in a locomotive pain clinic of one tertiary referral hospital. We analyzed epidemiologic and clinical characteristics, therapeutic responses, and prognostic factors for remission-failure at one-year after oral prednisolone treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3346/jkms.2018.33.e241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115692PMC
September 2018
4 Reads

West Nile Neuroinvasive Disease Presenting as Elsberg Syndrome.

Neurologist 2018 Sep;23(5):152-154

Division of Critical Care Neurology.

Introduction: Elsberg syndrome (ES) is a rarely recognized cause of cauda equina syndrome and lower thoracic myelitis, mainly linked to reactivation, or occasionally primary, infection with herpes simplex virus type 2. West Nile virus neuroinvasive disease is rarely considered in the differential diagnosis of patients with ES.

Case Report: A 63-year-old man with pancreatic cancer in remission and polymyalgia rheumatica on low-dose prednisone presented with a 10-day history of low-back pain and a viral-type illness with low-grade fever, nausea, and vomiting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/NRL.0000000000000189DOI Listing
September 2018
26 Reads

Application of 2012 EULAR/ACR criteria for polymyalgia rheumatica to Korean patients previously classified by Chuang and Hunder criteria or Healey criteria.

Int J Rheum Dis 2018 Oct 30;21(10):1838-1843. Epub 2018 Aug 30.

Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Aim: To apply 2012 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) criteria to Korean patients previously classified as polymyalgia rheumatica (PMR) by Chuang and Hunder criteria or Healey criteria and investigated whether they might be still reclassified as PMR or not.

Methods: We retrospectively reviewed the medical records of 113 previously classified PMR patients. We applied 2012 EULAR/ACR criteria without ultrasonography to PMR patients, and fulfilment required at least 4 points. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13343DOI Listing
October 2018
3 Reads

Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy.

RMD Open 2018 17;4(2):e000714. Epub 2018 Aug 17.

Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians-University Munich, Munich, Germany.

Immune checkpoint inhibitors (ICIs) may cause immune-related adverse events (IRAEs). Characterisation and data on treatment of musculoskeletal IRAEs are scarce. In this cohort study, patients receiving ICI therapy who experienced arthralgia were evaluated for the presence of synovitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2018-000714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109812PMC
August 2018
15 Reads

Additional costs of polymyalgia rheumatica with giant-cell arteritis.

Arthritis Care Res (Hoboken) 2018 Aug 29. Epub 2018 Aug 29.

Unité d'Evaluation Médico-Economique, Département d'Information Médicale, Centre Hospitalier Universitaire, Toulouse, F-31059, France.

Objective: To assess and compare direct costs between patients with giant-cell arteritis (GCA) associated or not with polymyalgia rheumatic (PMR), and to identify the additional cost drivers due to PMR.

Methods: We conducted a population-based, retrospective, cohort study using the French National Health Insurance System Database. Cost analysis was performed from the French health-insurance perspective and took into account direct medical and non-medical costs (€2014). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23736DOI Listing
August 2018
10 Reads

The availability of health information to patients with newly diagnosed polymyalgia rheumatica: results from the Polymyalgia Rheumatica (PMR) Cohort study.

Prim Health Care Res Dev 2018 Aug 8:1-5. Epub 2018 Aug 8.

6Senior Research Fellow in Epidemiology and Applied Statistics,Research Institute for Primary Care & Health Sciences,Keele University,Keele,UK.

AimThe aim of this study was to assess the provision of information to, and seeking of information by, patients newly diagnosed with polymyalgia rheumatica (PMR) in primary care.

Background: PMR is an inflammatory rheumatological condition of older people that can be treated with long-term oral glucocorticoids. Management usually requires the patient to understand the potential complications of treatment and the disease, as well as involvement in reducing treatment dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1463423618000543DOI Listing
August 2018
3 Reads

Support available for and perceived priorities of people with polymyalgia rheumatica and giant cell arteritis: results of the PMRGCAuk members' survey 2017.

Clin Rheumatol 2018 Dec 31;37(12):3411-3418. Epub 2018 Jul 31.

PMRGCAuk, London, UK.

Polymyalgia rheumatica and giant cell arteritis are relatively common, but under research inflammatory rheumatological conditions. This survey aimed to ascertain the matters in which patients feel they need support with these conditions and appraise how the Charity PMRGCAuk currently supports these needs and could do so in the future. PMRGCAuk members (n = 910) were invited to complete an on-line survey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-4220-1DOI Listing
December 2018
12 Reads

Temporal Arteritis Presenting as an Isolated Bilateral Abducens Nerve Palsy: A Rare Case of a 65-year-old Male.

Cureus 2018 May 22;10(5):e2667. Epub 2018 May 22.

Department of Neurology, University Of Kentucky College of Medicine.

Giant cell arteritis (GCA) or temporal arteritis (TA) is a granulomatous inflammation of medium to large-sized arteries. It may have a diverse presentation. The most common presenting symptoms of GCA are fever, malaise, unilateral headache, jaw claudication, polymyalgia rheumatica (PMR) and ophthalmoplegia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.2667DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054368PMC
May 2018
6 Reads